Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Beclomethasone dipropionate HFA Nasal Aerosol, Qvar
Beclomethasone dipropionate HFA · 2 trials · 4 indications
Adenosine challenge test were measured and described as PC 20 - the concentration that corresponded to a FEV1 impairment equal or bigger than 20%. The stage was also recorded
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 12 hours twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
| Arm | Type | Description |
|---|---|---|
| placebo, adenosine challenge test | PLACEBO_COMPARATOR | Controlled or partially controlled multiple trigger wheezing children received 4 weeks of placebo, preceded and succeeded by AMP challenge test, |
| Qvar, adenosine challenge test | ACTIVE_COMPARATOR | Patients will receive 4 weeks of inhale QVAR (HFA beclomethasone) 100µg through a spacer device, twice a day |
| BDP HFA 80 µg/day | EXPERIMENTAL | During the 2-week double-blind Treatment Period participants self-administered two actuations (one per nostril) of 40 micrograms (µg) BDP HFA and two actuations of placebo HFA once daily. |
| BDP HFA 160 µg/day | EXPERIMENTAL | During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of 40 µg BDP HFA once daily. |
| BDP HFA 320 µg/day | EXPERIMENTAL | During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily. |
| Placebo | PLACEBO_COMPARATOR | During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily. |
| Name | Type | Description |
|---|---|---|
| Beclomethasone dipropionate HFA | DRUG | 100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test |
| placebo | DRUG | inhalation twice a day for one month, preceded and followed by adenosine challenge test |
| Beclomethasone dipropionate HFA Nasal Aerosol | DRUG | Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol |
Inclusion Criteria: * clinical diagnosis of mild asthma * children aged between 3 - 6 years old * able to perform spirometry and adenosine challenge test * positive challenge test at the time of inclusion * without prophylactic treatment for asthma * signed informed consent to join the research by ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Beclomethasone dipropionate HFA is an investigational small molecule corticosteroid developed by Teva Pharmaceutical Industries Limited (TEVA). It is being studied in a hydrofluoroalkane propellant formulation for respiratory conditions, specifically asthma and seasonal allergic rhinitis. It is in Phase 2 clinical development.
Beclomethasone dipropionate HFA is being studied for asthma and seasonal allergic rhinitis, also known as hayfever. One Phase 2 trial evaluated it in preschool children with asthma and bronchial hyperresponsiveness, and another assessed it in patients 12 years and older with seasonal allergic rhinitis.
Beclomethasone dipropionate HFA is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the sponsor of the clinical trials studying this hydrofluoroalkane formulation of beclomethasone dipropionate.
Beclomethasone dipropionate HFA is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. Both of its recorded Phase 2 trials have been completed, and no trials are currently active.
Two completed Phase 2 trials studied beclomethasone dipropionate HFA. NCT01006655 examined the effect of HFA beclomethasone dipropionate Qvar on bronchial hyperreactivity in preschool children with asthma in Israel. NCT00854360 assessed the efficacy and safety of BDP HFA nasal aerosol in patients 12 years and older with seasonal allergic rhinitis in the United States.
Yes. Beclomethasone dipropionate HFA is also known as beclomethasone dipropionate HFA Nasal Aerosol. The nasal aerosol name reflects the intranasal formulation studied in seasonal allergic rhinitis, while the same active ingredient was also evaluated as an inhaled formulation in asthma.